JEOL (6951) Q4 2026 earnings summary

Executive summary

• Operating profit for FY2025 reached ¥26.0 billion, exceeding the previous forecast by ¥2.0 billion, with net profit at a record high and ROE at 15.7%.

• Net sales for FY ended March 31, 2026, declined 8.8% year-over-year to ¥179.4 billion, and operating profit dropped 26.7% year-over-year.

• Profit attributable to owners of parent rose 18.2% year-over-year to ¥22.1 billion, and comprehensive income increased 59.6% to ¥26.8 billion.

• Medical Equipment business was transferred to Sysmex Corporation as of April 1, 2026.

Financial highlights

• Net sales: ¥179.4 billion (YoY -8.8%), operating profit: ¥26.0 billion (YoY -26.7%), net profit: ¥22.1 billion (YoY +18.2%).

• Gross profit margin slightly decreased to 46.3% from 47.0% year-over-year; gross profit was ¥83.0 billion.

• Basic earnings per share increased to ¥432.58 from ¥365.55 year-over-year.

• Cash and cash equivalents at period end rose to ¥37.3 billion from ¥34.6 billion.

• Overseas sales ratio decreased to 67.2% from 71.2%.

Outlook and guidance

• FY2026 net sales forecast at ¥164.0 billion, reflecting the impact of the Medical Equipment business transfer.

• Operating profit forecast for FY2026 is ¥26.5 billion.

• Profit attributable to owners of parent forecast at ¥21.3 billion for FY2026.

• Dividend per share forecast for FY2026 is ¥132.00, with a payout ratio of 30.5%.

• Market recovery for Multi-Beam Mask Writers is slow; performance expected to remain flat year-over-year.